文献速递淋巴瘤

血清中EB病毒DNA作为儿童和青少年霍奇金淋巴瘤早期预后标志物

Epstein-Barr virus DNA in serum as an early prognostic marker in children and adolescents with Hodgkin lymphoma.
PubMed 文献 · Blood Adv · 2017-04-24

研究纳入儿童肿瘤协作组AHOD0031试验的儿童霍奇金淋巴瘤患者,在基线和治疗开始后8天检测无细胞血EBV DNA,基线EBV DNA与肿瘤EBV相关,治疗8天后EBV DNA预测无事件生存较差。

要点

  • 基线无细胞血EBV DNA与肿瘤中EBV存在相关
  • 治疗开始后8天EBV DNA可预测较差的 无事件生存
  • 无细胞血EBV DNA作为霍奇金淋巴瘤肿瘤反应不足标志物需进一步研究

核心结论

  • 无细胞血EBV DNA作为霍奇金淋巴瘤肿瘤反应不足标志物需进一步研究。

研究设计与样本

  • 研究纳入儿童肿瘤协作组AHOD0031试验的儿童患者,在基线和治疗开始后8天检测无细胞血EBV DNA。

主要发现

  • 基线时无细胞血EBV DNA与肿瘤中EBV存在相关。
  • 治疗开始后8天EBV DNA预测较差的无事件生存。

局限性

  • 原文结论指出无细胞血EBV DNA作为霍奇金淋巴瘤肿瘤反应不足标志物需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Assay of cell-free DNA in blood offers an approach to assessment of tumor DNA. We sought to determine whether Epstein-Barr virus (EBV) DNA in cell-free blood is also a good surrogate for the presence of tumor DNA in children with Hodgkin lymphoma, as it is in adults, and whether it correlates with pediatric outcomes. Pediatric patients enrolled in a Children's Oncology Group trial (AHOD0031) were studied at baseline and at 8 days after the initiation of treatment. At baseline, EBV DNA in cell-free blood correlated with the presence of EBV in tumor, and EBV DNA 8 days after the initiation of therapy predicted inferior event-free survival. EBV DNA in cell-free blood warrants further investigation as a marker of inadequate tumor response in Hodgkin lymphoma. This trial was registered at www.clinicaltrials.gov as #NCT00025259.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Welch JJG, Schwartz CL, Higman M, et al. Epstein-Barr virus DNA in serum as an early prognostic marker in children and adolescents with Hodgkin lymphoma. Blood Adv. 2017. PMID: 29296710. doi:10.1182/bloodadvances.2016002618

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。